NeoGenomics price target raised to $23 from $21 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on NeoGenomics to $23 from $21 and keeps a Buy rating on the shares. The analyst cites the company’s “strong” Q4 earnigns beat and above-consensus guidance, stating that the firm has been “impressed” with its fundamentals since the new management team has taken over. BTIG adds it has a “growing sense” that much of NeoGenomics’ operational strength in recent quarters is durable, particularly in areas like revenue cycle management and test mix which have a far way to go from here.